Trial Profile

A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN Smallpox Vaccine to ACAM2000 in 18-40 Year Old Healthy Vaccinia-naive Subjects

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Modified vaccinia Ankara (Primary) ; ACAM 2000
Indications Smallpox
Focus Pharmacodynamics; Registrational
Sponsors Bavarian Nordic

Most Recent Events

20 Feb 2020 According to a Bavarian Nordic media release, in Jan 2020, the company completed the sale of the Priority Review Voucher, granted by the FDA in connection with the approval of JYNNEOS in 2019.
14 Nov 2019 Results published in the New England Journal of Medicine
14 Nov 2019 According to a Bavarian Nordic media release, results from this trial are published in The New England Journal of Medicine (NEJM).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com